Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade the company's valuation. Learn more on BHC stock here.

Bausch+Lomb ($BLCO), a contact lens supplier, is exploring a sale to address concerns raised by its lenders like Apollo Global Management ($APO)

The stock of eyecare company Bausch + Lomb Corp. was up 18% early Monday, after the Financial Times reported that the company is considering selling itself as a way to extricate itself from its indebted parent.

Bausch Health retained an 88 per cent shareholding in the eye care subsidiary after listing the group in 2022. But it planned to offload the remainder of shares by striking a deal with its investors to exchange Bausch Health stock for Bausch + Lomb stock.

Bausch + Lomb (BLCO) stock will be in focus as company is exploring a sale to address concerns raised over its separation from Bausch Health (BHC). Read mroe here.

Key Takeaways Bausch + Lomb is discussing a possible sale that would separate it from its parent company, Bausch Health Cos.Bausch Health is saddled with debt of $21 billion, nearly $10 billion of which is set to mature in 2027.

Bausch + Lomb (NYSE:BLCO) is exploring a potential sale as part of an effort to resolve issues related to its separation from parent company Bausch Health, which is burdened with significant debt, as per a Financial